Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Sandostatin LAR® Depot in Patients With Primary Insulin Hypersecretion (PIH) and at Least Moderate Obesity

NCT00094146 is registered in ClinicalTrials.gov with Novartis as lead sponsor.

NCT NCT00094146
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00094146 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Sandostatin LAR® Depot in Patients With Primary Insulin Hypersecretion (PIH) and at Least Moderate Obesity
Lead sponsor
Novartis
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2002
Completion date
December 31, 2002
Enrollment
160
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

obesity, primary insulin hypersecretion